Benefits to You

Get instant access to helpful resources, networking and discounts on AUTM events.
View member benefits » 

Volunteer with AUTM

Get involved by supporting a committee that suits your interests and availability.

Volunteer today » 


Call for Nominations

2015 Board of Directors

Deadline September 9

The AUTM Nominations and Awards Committee is pleased to invite all AUTM members to submit nominations for candidates to serve on the 2015 AUTM Board of Directors for the following positions:

  • President-Elect
  • Vice President for Advocacy
  • Vice President for Membership Development –Western Hemisphere
  • Vice President for Communications
  • Board Members At Large (3)

Learn more > > > 

Track H

H8 Sharing Data and Assets Across Industry and Academia to Drive the Science Base and Innovation

Track: Industry - Academic Relations
Target Audience: All Audiences
Moderator: Malcolm Skingle, Ph.D., GlaxoSmithKline
Speakers: Rowan Douglas, Willis Research Network
  Helene Rutledge , GlaxoSmithKline
  Bin Yan, Ph.D., LL.B. , University of Miami W.H Coulter Center

Increasingly, technology-driven companies are looking to de-risk research and development projects by sharing data and proprietary assets with selected academics in order to expand parts of the science base and to increase their internal knowledge. Many of these projects are co-funded by funding agencies on the assumption that the data generated is deposited into the public domain for all to access. This has driven an interesting dynamic where the corporate company has wanted increased levels of openness and some universities wish to adopt a more secretive approach. Several companies driven by global technology have developed innovative business models with certain universities in recent years in order to increase R&D productivity. These models will be described in detail in order to share what many in industries now consider to be best practice. Recent novel examples from different industrial sectors will be described, including business models from GlaxoSmithKline, Proctor and Gamble, and Willis Ltd, a company specializing in risk adjustment.

Return to schedule